(Credit: Getty Images)

SHARE THIS 
ARTICLE

You are free to share this article under the Attribution 4.0 International license.

TAGS

• LEAD
• MORTALITY

UNIVERSITY

 CARNEGIE MELLON UNIVERSITY

Infant mortality is tied to the concentration of lead in the air, according to a new study.

Concentrations of lead in the air remain substantial in developed and developing countries, largely the result of industrial emissions.

Even with the decline in lead in gasoline, developed countries, including the United States, still have substantial air lead emissions and in part as a result, blood lead levels in children are high worldwide.

In a new study, researchers used data on lead emissions in the air to estimate the effects of air lead concentration on infant mortality. The study found a statistically significant relation between air lead concentration and infant mortality.

The study is a National Bureau of Economic Research Working Paper.

“Although many studies have examined the adverse effects of lead on children’s cognitive and behavioral outcomes, few have analyzed the effect of exposure to lead on infants’ health, so we know little about the extent of harm to infants’ health from airborne lead in settings with modern medical care and at modern exposure levels,” explains Karen Clay, a professor of economics and public policy at Carnegie Mellon University’s Heinz College of Information Systems and Public Policy, who led the study.

Lead is known to cause adverse health effects in humans across a range of exposures. In this study, researchers used data on lead emissions from the US Toxics Release Inventory (TRI), which was created in 1986 in response to chemical releases in Bhopal in 1984 and in West Virginia in 1985; the TRI covers over 650 chemicals. The causal effect of lead on infant mortality is identified by annual variation in air fugitive lead emissions interacted with wind speed near reporting plants, which together determine local ambient lead concentration.

The researchers also analyzed lead monitor data from the Environmental Protection Agency (EPA)’s Air Quality System, wind data from the National Centers for Environmental Information, and infant health data from the National Vital Statistics system of the National Center for Health Statistics. The study included 127 US counties that have plants with lead emissions within 2 miles of EPA lead monitors and within 10 miles of a wind monitor.

Higher concentrations of lead in the air caused higher levels of infant mortality in infants’ first month and first year, suggesting that both in utero and environmental exposures matter. In addition, higher lead concentration boosted deaths from low birthweight, sudden unexplained infant death, and respiratory and nervous system causes.

“Back-of-the-envelope calculations indicate that declines in fugitive lead emissions prevented 34 to 59 infant deaths per year, generating benefits of $380 million to $670 million annually,” says Edson Severnini, an associate professor of economics at Boston College, who coauthored the study.

“In the United States, industrial firms and the aviation industry still emit hundreds of thousands of pounds of lead into the air,” notes Xiao Wang, assistant professor of economics and trade at Hunan University, who coauthored the study. “Our new estimates can inform investments in reducing air lead emissions and soil cleanups.”

Funding for the research came from Heinz College at Carnegie Mellon University.

Source: Carnegie Mellon University

Original Study DOI: 10.3386/w33447 

(Credit: Getty Images)

SHARE THIS 
ARTICLE

You are free to share this article under the Attribution 4.0 International license.

TAGS

• FAMILIES
• PARENTS

UNIVERSITY

 UNIVERSITY OF CHICAGO

In a new podcast, a developmental psychologist explains how parents can best invest time to close the education gap.

New federal data paints a stark picture: American children are falling behind in reading and test scores, with the gap between advantaged and disadvantaged kids growing wider. But is this really just a problem of money?

University of Chicago developmental psychologist Ariel Kalil has spent her career studying how parents influence childhood development—not just through resources, but through daily habits and interactions.

On this episode of the Big Brains podcast, Kalil digs into the surprising science behind parental engagement, the behavioral biases that shape parenting decisions, and why simple interventions—like 15 minutes of reading a day—can have an outsized impact. Plus, she explains how AI and behavioral economics might provide new solutions for supporting parents in an era of rising inequality.

https://player.simplecast.com/a423e479-48be-4044-8966-2ffb4f45512f?dark=false

Read the transcript of this episode.

Source: University of Chicago

(Credit: Getty Images)

SHARE THIS 
ARTICLE

In an extensive and up-to-the-minute review of research in this domain, researchers from the University of California, Irvine illuminate the profound impacts of these adverse childhood experiences on brain development and introduce new paths for understanding and tackling them.

Their study in Neuron examines the mechanisms behind the long-term consequences of childhood stress (adversity). Despite extensive research spanning over seven decades, the authors point out that significant questions remain unanswered.

For example, how do adults—from parents to researchers—fully comprehend what is perceived as stressful by an infant or child? Such conceptual queries, as well as the use of cutting-edge research tools, can provide a road map, guiding experts toward developing innovative methods and providing solutions to this pressing mental health issue.

“Our research suggests that the unpredictability of a child’s early environment may be just as important as more traditionally recognized forms of adversity, such as abuse or neglect,” says lead author Tallie Z. Baram, a professor of pediatrics at the University of California, Irvine and one of the world’s leading researchers in this field.

“Our review has important implications for how we approach early intervention and prevention strategies.”

She and coauthor Matthew Birnie, a UC Irvine postdoctoral scholar, identify several key areas for further investigation:

• What does the developing brain perceive as stressful?
• Which aspects of stress most significantly influence brain maturation?
• Which developmental ages are most vulnerable to adversity?
• What are the molecular mediators of stress effects on the brain?
• How can transient stressful experiences lead to enduring dysfunction?

One notable discovery is a novel form of early-life stress: unpredictable sensory inputs from caregivers and the environment. This factor plays a substantial role in adverse neurodevelopmental outcomes, even after controlling for well-known adverse childhood experiences, which are collectively referred to as ACEs.

The review highlights the limitations of current ACE scoring systems in accurately predicting individual outcomes and underscores the complexity of early-life stress. Emerging factors, such as societal and anthropogenic characteristics like inequality and pollution, are gaining recognition as potential contributors.

Animal models have been instrumental in unraveling the mechanisms underlying brain development effects. Research has revealed that different types of stress can yield distinct outcomes, influenced by the nature and timing of stress, as well as species, strain, and sex variations.

At the molecular level, early-life stress can substantially alter neuronal gene expression through epigenetic mechanisms. These changes may lead to long-term modifications in how the brain responds to subsequent experiences. At the circuit level, early stress can disrupt the maturation of brain networks by interfering with crucial developmental processes, including neuronal oscillations and synaptic pruning.

“We’re gradually comprehending how early-life stress can ‘reprogram’ the brain at multiple levels, from individual molecules to entire neural circuits. This knowledge presents new avenues for targeted interventions,” Baram says.

The review also identifies key molecular mediators of early-life stress effects, including glucocorticoids and neuropeptides like corticotropin-releasing hormones. Ongoing research is uncovering novel roles for these molecules in specific neural circuits affected by early stress.

In light of these findings, the researchers propose redefining early-life stress as “early-life adversity” to better encompass the diverse experiences that can affect brain development, even those not traditionally perceived as stressful.

“This review emphasizes the need for a more comprehensive understanding of early-life adversity,” Baram says. “By focusing on how the developing brain processes and responds to these experiences, we can develop more effective strategies to prevent and mitigate their long-term effects.”

The researchers suggest increased funding for and attention to this critical area of study, highlighting its potential to enhance mental health outcomes and reduce the societal burden of early-life adversity.

The National Institutes of Health as well as the Hewitt Foundation for Biomedical Research supported the work.

Source: UC Irvine

Original Study DOI: 10.1016/j.neuron.2025.02.016

MARLTON, N.J., March 12, 2025 /PRNewswire/ — A growing number of women who received Depo-Provera injections are coming forward with serious health concerns following new research linking the contraceptive drug to an increased risk of meningioma, a type of intracranial tumor. Many individuals who used progestogen-only injections such as Depo-Provera (DMPA, medroxyprogesterone acetate) for extended periods have reported symptoms such as chronic headaches, vision problems, dizziness, memory impairment, and seizures—common neurological symptoms associated with brain masses.

If you or a loved one developed a meningioma after long-term use of Depo-Provera, legal options may be available. However, due to strict statutes of limitations, those affected have only a limited window of time to take action. In some states, the statute of limitations for product liability cases is just one year from the date of injury or discovery. Console & Associates P.C. is reviewing cases for women who have been diagnosed with progesterone-induced meningiomas after prolonged use of this birth control injection.

What Is the Connection Between Depo-Provera and Meningiomas?

Depo-Provera is a progestin-based contraceptive shot used by millions worldwide for birth control, as well as for treating endometriosis, menstrual irregularities, and other hormonal conditions. However, a March 2024 study published in the British Medical Journal uncovered a troubling link. Researchers from France’s National Agency for Medicines and Health Products Safety determined that prolonged use of medroxyprogesterone acetate (DMPA) increases the risk of developing meningiomas by five and a half times.

Meningiomas are intracranial tumors that form in the membranes surrounding the brain and spinal cord. While typically noncancerous, they can still cause severe neurological symptoms, including headaches, blurred vision, difficulty speaking, and cognitive impairment. Larger tumors may require surgery, radiation, or lifelong medical monitoring, posing significant health and financial burdens.

How Many Women Could Be at Risk?

Depo-Provera has been widely prescribed since its FDA approval in 1992, with millions of women worldwide using the contraceptive shot for birth control. In the United States alone, nearly 1.5 million women rely on Depo-Provera annually, according to the Guttmacher Institute. Given the newly identified risks of meningioma, a substantial number of women may have unknowingly developed progesterone-induced meningiomas after prolonged use.

Did Pfizer Fail to Warn About the Risks?

Despite growing concerns about the link between Depo-Provera and intracranial tumors, Pfizer—the drug’s manufacturer—did not include this risk on its warning labels for decades. The company only recently acknowledged the potential danger, confirming plans to update patient information leaflets and product labels.

For years, women trusted Depo-Provera as a safe and effective birth control injection, unaware of the long-term health risks. Without clear warnings, many individuals lacked the information needed to make informed healthcare decisions. Now, countless women are left with neurological symptoms, permanent disabilities, and costly medical treatments—all of which could have been avoided had the manufacturer acted sooner.

Women who used Depo-Provera (DMPA, medroxyprogesterone acetate) for more than a year and were later diagnosed with meningiomas may have grounds for legal action. Lawsuits could seek compensation for medical expenses, lost wages, long-term care costs, and emotional distress.

What Are Your Legal Options If You Were Diagnosed with a Brain Tumor?

Those diagnosed with meningiomas after using Depo-Provera may qualify for a mass tort lawsuit, a type of legal action allowing multiple plaintiffs to hold the manufacturer accountable. Due to strict statutes of limitations, women affected by Depo-Provera birth control injection side effects must act quickly to protect their legal rights.

Console & Associates P.C. is currently evaluating claims for women who meet the following criteria:

• Used Depo-Provera (DMPA, medroxyprogesterone acetate) for one year or longer;
• Received a meningioma diagnosis; and
• Experienced headaches, blurred vision, seizures, memory loss, or other neurological symptoms

Many individuals facing a meningioma diagnosis require extensive medical treatments, including surgery, radiation therapy, or lifelong neurological monitoring. A successful lawsuit can provide the financial support necessary to cover these expenses, ensuring that those affected receive the care they need. However, holding Pfizer accountable is not just about compensation—it is about ensuring that pharmaceutical companies prioritize patient safety over profits.

The mass tort lawyers at Console & Associates, P.C. are dedicated to advocating on behalf of those injured by dangerous and defective drugs. Anyone interested in learning more about Depo-Provera Lawsuits should contact the firm for a no-obligation consultation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Console & Associates, P.C. 

866-778-5500

info@consoleandassociates.com

View original content: https://www.prnewswire.com/news-releases/console–associates-pc-investigating-depo-provera-injuries-meningioma-brain-tumor-risks-for-women-using-injectable-contraceptives-302400275.html

SOURCE Console & Associates, P.C.

Research Conducted By NYU’s Music & Auditory Research Lab Validates Music as a Therapeutic Intervention for Mental Health and Highlights the Importance of Evidence-Based Composition

NEW YORK, March 12, 2025 /PRNewswire/ — Spiritune, a leading therapeutic music app, is proud to announce the publication of its research into the PLoS ONEscientific journal, marking a significant advancement in the field of music neuroscience and mental health. The peer-reviewed study adds to the growing body of evidence supporting music’s potential as a digital therapeutic for improving mental health outcomes.

The study revealed that Spiritune’s science-driven approach to music composition is 4 times more effective at reducing negative emotional states compared to other audio conditions, including mainstream music and playlists that claim cognitive benefits. It also demonstrated Spiritune’s unique ability to improve processing speed during listening – setting it apart as the only music intervention to achieve this outcome.

The findings highlight a crucial distinction: not all therapeutic music is created equal. While many playlists claim stress-relief or performance benefits, Spiritune’s study shows that music composed using principles from music neuroscience and music therapy yields measurable therapeutic outcomes.

“Music is powerful, but therapeutic outcomes require more than marketing promises,” said Jamie Pabst, Founder of Spiritune. “This study validates what we’ve always believed in: music needs to be intentionally created and scientifically grounded to truly impact mental health. Spiritune represents the next frontier in mental health by turning music into medicine.”

“This study validates the capacity of simple music listening during daily routines to effectively modulate core dimensions of mental health” said Daniel Bowling, a neuroscientist at Stanford and co-author on the paper. “It further shows that principles from music neuroscience and music therapy can be systematically applied to guide original compositions towards specific therapeutic goals in the general population.”

As mental health challenges continue to rise globally, this research emphasizes the potential of music to augment other forms of treatment, providing listeners with a safe way to feel better that is available on demand. Spiritune’s long-term commitment to scientific research and its mission to create and redefine music’s role in popular culture and the mental health ecosystem shine through this landmark achievement.

The study was recently published in PLoS One on February 12, 2025. It provides further details about Spiritune’s innovative approach to music creation and application, as well as methodology and results to drive further progress and understanding. While more remains to be done, Spiritune’s research offers actionable insights for mental health professionals and anyone seeking to integrate effective music-based therapies into daily life or health care practices.

For interviews or information contact press@spiritune.com.

About Spiritune

Spiritune is a digital therapeutic music app that combines music neuroscience and music therapy to address key dimensions of mental health, including emotional regulation and cognitive functioning. Backed by scientific research, Spiritune offers personalized playlists designed to enhance well-being, productivity, and performance.

For more information, visit www.spiritune.com.

View original content: https://www.prnewswire.com/news-releases/spiritunes-peer-reviewed-music-and-mental-health-study-published-in-plos-one-302400280.html

SOURCE Spiritune

Published 12:16 PM PDT, March 12, 2025Share

~Resort Company Shares Bold Growth Plans with Three New Resorts Across Three Islands and a Major Expansion of its Award-Winning Turks and Caicos Resort~

MONTEGO BAY, Jamaica, March 12, 2025 /PRNewswire/ — Beaches Resorts announced plans to invest nearly US $1 billion in the expansion of its leading family all-inclusive vacation brand, doubling its footprint within the next five years.

Adam Stewart, Executive Chairman of Beaches Resorts, unveiled the groundbreaking announcement and ambitious expansion plans at the company’s Made of Caribbeanglobal launch event held in New York City. Stewart shared the announcement of new destinations for the Beaches brand including: a new Beaches in Barbados, plans for a Beaches in Exuma, The Bahamas, and Beaches Runaway Bay in Jamaica – along with a sneak peek of the newTreasure Beach Village coming to Beaches Turks and Caicos.

Beaches Resorts was founded in 1997 with locations in Jamaica and Turks and Caicos, as the family-friendly evolution of Sandals Resorts. Beaches Negril and Beaches Turks and Caicos introduced a premium, all-inclusive experience tailored specifically for families. Since then, Beaches has established itself as the premier vacation for travelers of all ages with signature inclusions such as Caribbean Adventures with Sesame Street®, Kids Camps, epic waterparks and its groundbreaking Autism Program certified `by the International Board of Credentialing and Continuing Education Standards (IBCCES).

“As a family from the Caribbean, we have a deep love for our islands, and it’s incredibly gratifying to draw inspiration from our guests,” said Stewart. “Our growth strategy is rooted in meeting their wants, with the importance of family time being at the core of our brand’s DNA. We know that now, more than ever, families are prioritizing connection and seeking enriching, multigenerational vacations. We are committed to not only meeting this demand but going above and beyond to wow them with new product offerings and provide unforgettable shared experiences.”

Beaches Resorts to Make its Debut in Barbados 

Joining existing sister properties Sandals Barbados and Sandals Royal Barbados, Beaches Barbados will open as the inaugural Beaches on the island. Breaking ground in late 2025, the new resort will offer 600 rooms – from king suites and two-queen designs to nearly 3,000-square-foot, four-bedroom suites complete with a private oceanfront balcony. Designed in ‘Bajan Style,’ a grand and luxurious take on Caribbean Georgian Style, the resort’s standout will include a dedicated ‘Main Street’ – a winding resort center featuring dining and shopping opportunities, as well as high-energy family zones from outdoor performance stages to a modern sports bar and arcade.

Beaches Resorts Steps Foot in The Bahamas 

Set upon 500 acres in the Out Islands, Beaches Exuma will be the brand’s first appearance in The Bahamas. The brand is collaborating with the Bahamian Government to finalize an agreement for the conversion of the resort from Sandals Emerald Bay. The transformation into Beaches Exuma will reconfigure the property’s 249 keys into a mix of accommodations, including multi-bedroom villa suites. While the new resort will feature 12 restaurants, a Kids Camp, signature splash park, full-service Red Lane Spa, and the brand’s exclusive partnership with Sesame Street®, the destination itself – with its renowned crystalline waters – will be the star attraction. Guests can also enjoy complimentary green fees at the Greg Norman-designed 18-hole Emerald Bay Golf Course.

Beaches Runaway Bay Resort 

Located midway between Ocho Rios and Montego Bay on Jamaica’s renowned North Coast, Beaches Runaway Bay will feature an estimated 400 expansive one, two, three and four-bedroom suites and villas, designed with extended families in mind. Guests can expect dedicated wellness areas and new activities such as skateboarding, bike trails, a climbable treehouse and access to Runaway Bay Golf Club and its par-72, 18-hole championship golf course, plus organic farm-to-table dining.

Treasure Beach Village at Beaches Turks and Caicos Now Accepting Reservations 

Beaches Resorts will open the doors to a brand new village, Treasure Beach, at Beaches Turks and Caicos, bringing the property to 858 total keys across its soon-to-be six villages. Designed for friends and families traveling together, Treasure Beach Village will add 101 keys – all of them suites – including large four-bedroom villas along the beach welcoming up to 10 guests each and overlooking the crystal clear Grace Bay waters. Treasure Beach Village will debut its first-ever food hall featuring an international array of dining options, as well as introduce Sandals guest favorite, Butch’s Island Chophouse, to the brand. The resort is now accepting reservations.

These additions to the Beaches Resorts portfolio come on the heels of a recent expansion to the brand’s flagship resort in Jamaica, Beaches Negril, where the new three-story Firesky Reserve Villas welcome families of up to 10, complete with four bedrooms, beautifully appointed living areas, a private pool and more – all steps from the sand; along with the Eventide Penthouse Collection, welcoming up to 18 guests with access to a rooftop terrace ideal for stargazing and soaking in the soothing breeze.

For more information and to book, visit www.beaches.com.

About Beaches® Resorts: 

Family-owned Beaches Resorts is the Caribbean playground where families can live their best island life. With locations in Turks and Caicos and Jamaica, and additional resorts to come in Barbados and The Bahamas, Beaches offers fun-forward family all-inclusive vacations – from a dynamic selection of restaurants and vibrant food trucks to all-you-can-enjoy water sports, live shows and epic water parks. Kids discover magic with Caribbean Adventures with Sesame Street®, Kids Camps, and hangouts for teens, while parents enjoy peace of mind with certified nannies, sensory-friendly programming and multi-bedroom villas perfect for bringing generations together. At Beaches, every member of the family finds joy, connection and memories made to last a lifetime. For more information about Beaches Resorts, visit www.beaches.com.

Media Contact 

mediarelations@uvi.sandals.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/beaches-resorts-announces-nearly-us-1b-in-expansion-plans-for-its-premier-family-travel-brand-302400284.html

SOURCE Beaches Resorts

VANCOUVER, BC, March 12, 2025 /CNW/ – Trading resumes in:

Company: Angkor Resources Corp.

TSX-Venture Symbol: ANK

All Issues: Yes

Resumption (ET): 11:45 AM

CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Published 8:28 AM PDT, March 12, 2025

LOS ANGELES–(BUSINESS WIRE)–Mar 12, 2025–

Curly Culture, the trusted digital destination for multicultural beauty education founded by digital pioneer Ava Pearl, today announced a strategic partnership with Society 18, the premier influencer management and marketing agency focusing on multiethnic and multicultural influencers and talent. The collaboration unites two women-led organizations committed to celebrating natural hair and amplifying multicultural beauty voices across platforms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312745449/en/

Society 18 hosts a creator dinner at STK NYC for NYFW. Photo Credit: Keyla Navarro

The partnership will feature its first activation at this year’s CurlyCon LA on March 22, where Society 18 creators will participate in a dedicated Creator Lounge that offers attendees opportunities to connect with diverse beauty influencers, including Alyssa Marie and Yanina Oyarzo. With a collective reach exceeding 20 million, both organizations will create new monetization opportunities for creators while offering brands expanded access to authentic voices in the beauty space. Beyond CurlyCon LA, the companies will team up to fuel additional activations throughout the year, providing Society 18’s roster of creators with speaking, hosting, and content creation opportunities.

“Partnering with Society 18 aligns perfectly with our mission of celebrating textured hair and its cultural significance,” said Pearl. “This collaboration allows us to expand our community by introducing new voices who understand the journey of embracing natural beauty while creating more opportunities for creators to connect with brands and audiences who appreciate authentic representation.”

Founded in 2019, Society 18 currently represents more than 40 creators who are predominantly women of color. The agency has helped increase creators’ revenues by up to five times their previous earnings through strategic brand partnerships, with over 3,000 brand campaigns executed to date.

“The natural hair community has always been at the core of Society 18, with about 70% of our creators starting in the natural hair space,” said Pamela Zapata, founder and CEO of Society 18. “By aligning with Curly Culture—which celebrates all textures and types of natural hair—we can create meaningful opportunities for our creators while furthering our shared mission of making natural, curly hair seen as beautiful across all cultures.”

For more information, contact info@curlyculture.com.

About Curly Culture

Founded by digital pioneer and entrepreneur Ava Pearl in 2023, Curly Culture has established itself as a trusted digital destination for multicultural beauty education and empowerment. Through its popular series, including Curlfessions and Between Us Curls, the platform brings authentic voices and experiences to a global audience seeking community and expert guidance on textured hair care.

About Society 18

Founded in 2019, Society 18 has emerged as the premier talent management and marketing agency for brands and partners seeking collaboration with multiethnic and multicultural content creators and talent. Boasting a roster of diverse creators, the bicoastal agency remains at the forefront of the talent and influencer landscape. Society 18 delivers unparalleled one-on-one strategic counsel for talent management endeavors and businesses aiming to enhance their brand presence through meticulously crafted and impactful creator and digital campaigns.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250312745449/en/

CONTACT: Flight PR

Alysha Light

alysha@flightpr.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: ONLINE RETAIL LUXURY BLOGGING CONSUMER FASHION COSMETICS RETAIL PUBLIC RELATIONS/INVESTOR RELATIONS MARKETING WOMEN ADVERTISING COMMUNICATIONS

SOURCE: Curly Culture

Copyright Business Wire 2025.

PUB: 03/12/2025 11:28 AM/DISC: 03/12/2025 11:28 AM

http://www.businesswire.com/news/home/20250312745449/en

LONDON–(BUSINESS WIRE)–Mar 12, 2025–

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study. 1 The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV who were already stable on treatment. It was also well tolerated by participants.

These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S.

Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “As leaders in long-acting injectable innovation, we are building on the positive patient and physician experience we have with Cabenuva and pioneering the next generation of long-acting treatment options. The EMBRACE study demonstrated that VH109, a CD4-binding broadly neutralising antibody, administered every four months with cabotegravir, achieved high efficacy and was well tolerated through six months. We’re looking forward to continuing the development of VH109 as a component of our future ultra long-acting regimens.”

Results from the EMBRACE study at the six-month primary endpoint showed that 96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group. VH109 was administered in both arms every four months, combined with monthly CAB LA. Confirmed virologic failure was observed in two participants from each VH109 group.

Overall, 4% of the IV group and 6% of the SC group had HIV-1 RNA levels of 50 copies/mL or higher, compared to none in the standard-of-care group when measured at month six.

VH109 was generally well tolerated, though infusion site reactions were more frequent with SC administration, occurring in 14% compared to none with IV administration. Adverse events specific to the use of study medication were reported in 64% of the IV group and 65% of the SC group, with 16% of participants in the SC group experiencing grade 3-4 adverse events (erythema). No participants in the IV group experienced a grade 3-4 adverse event.

Based on the favourable results seen in the trial, ViiV Healthcare will be progressing a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two trial.

About Cabenuva (cabotegravir + rilpivirine) Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland Unlimited Company. Rilpivirine tablets are approved in the U.S. and when used with cabotegravir is indicated for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse transcriptase, which stops the virus from multiplying.

Please consult the full Prescribing Information.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2024.

Registered in England & Wales: GSK plc 

GSK plc 

No. 3888792

ViiV Healthcare Limited 

No. 06876960

Registered Office: 79 New Oxford Street 

79 New Oxford Street 

London 

WC1A 1DG

ViiV Healthcare Limited 

GSK Medicines Research Centre 

Gunnels Wood Road, Stevenage 

SG1 2NY

References

___________________________________

1 Taiwo, B et al. VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025), 9-12 March, San Francisco, CA

View source version on businesswire.com:https://www.businesswire.com/news/home/20250312440906/en/

CONTACT: ViiV Healthcare enquiries:

Media:

Rachel Jaikaran

+44 (0) 78 2352 3755

(London)Ken Inchausti

+1 732 690 6938

(Philadelphia)GSK enquiries:

Media:

Tim Foley

+44 (0) 20 8047 5502

(London)Sarah Clements

+44 (0) 20 8047 5502

(London)Kathleen Quinn

+1 202 603 5003

(Washington DC)Alison Hunt

+1 540 742 3391

(Washington DC)Investor Relations:

Annabel Brownrigg-Gleeson

+44 (0) 7717 618834

(London)James Dodwell

+44 (0) 20 8047 2406

(London)Mick Readey

+44 (0) 7990 339653

(London)Camilla Campbell

+44 (0) 7803 050238

(London)Steph Mountifield

+44 (0) 7796 707505

(London)Jeff McLaughlin

+1 215 751 7002

(Philadelphia)Frannie DeFranco

+1 215 751 4855

(Philadelphia)

KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: AIDS HEALTH FDA GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: ViiV Healthcare

Copyright Business Wire 2025.

PUB: 03/12/2025 11:30 AM/DISC: 03/12/2025 11:32 AM

http://www.businesswire.com/news/home/20250312440906/en

ROME–(BUSINESS WIRE)–Mar 12, 2025–

Exein, the embedded IoT cybersecurity company, and Supermicro, a global leader in application-optimized total IT solutions, have announced a partnership to redefine embedded security. Exein and Supermicro’s collaboration will see Exein’s cutting-edge embedded security solutions integrated into Supermicro’s industry-leading hardware, ensuring unprecedented protection for enterprises worldwide.

Together, Exein and Supermicro are raising the bar for cybersecurity in edge computing, IoT, and critical infrastructure—securing the future, one device at a time. With Exein’s AI-driven security built directly into Supermicro’s hardware, businesses can now deploy infrastructure with zero-trust security from the ground up—ensuring resilience against evolving cyber threats.

“We are honored to partner with Supermicro to bring Exein’s next-generation embedded security to their industry-leading solutions. This collaboration ensures that security is not just an add-on, but an integral part of the hardware ecosystem—empowering businesses with AI-driven, zero-trust protection from the core. With Exein’s technology, Supermicro’s offerings will not only be more resilient against evolving cyber threats but also fully compliant with the Cyber Resilience Act, setting a new standard for secure infrastructure worldwide.” – Gianni Cuozzo, CEO of Exein.

The partnership with Supermicro follows Exein’s significant industry partnerships in recent months with MediaTek and Integral Systems. As a result of these partnerships Exein’s advanced cybersecurity technology will be embedded in billions of IoT devices worldwide. In 2024, Exein successfully closed a €15m Series B round to drive its ambitious global expansion plans across Europe, the US and Asia.

ENDS

About Exein

Exein is a leading embedded IoT cybersecurity company with offices in Italy, Germany, and the US. Focused on device-level security, Exein embeds advanced security measures directly into device software, leveraging edge AI for real-time threat detection and response. Exein technologies protect over 1 billion devices daily across sectors including industrial, automotive, and aerospace, aiming to set the global standard for embedded cybersecurity and build the immune system for digital life.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250312141274/en/

CONTACT: Ellie Munford

exein@fieldhouseassociates.com

KEYWORD: UNITED STATES UNITED KINGDOM NORTH AMERICA ITALY EUROPE GERMANY

INDUSTRY KEYWORD: ELECTRONIC DESIGN AUTOMATION SECURITY TECHNOLOGY SOFTWARE INTERNET HARDWARE

SOURCE: Exein

Copyright Business Wire 2025.

PUB: 03/12/2025 11:31 AM/DISC: 03/12/2025 11:32 AM

http://www.businesswire.com/news/home/20250312141274/en